TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house ...
Patients with narcolepsy have a significantly greater risk for cardiovascular disease (CVD) and major adverse cardiovascular events (MACE), even after accounting for stimulant use. These findings were ...
Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor ...
Several drug makers are racing to win approval of a new class of drugs that could transform how the rare sleep disorder is treated.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution ...
DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback